- Home
- HOLO vs AXDX Comparison
HOLO vs AXDX Comparison
Compare HOLO & AXDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- AXDX
- Stock Information
- Founded
- HOLO 2018
- AXDX 1982
- Country
- HOLO China
- AXDX United States
- Employees
- HOLO N/A
- AXDX N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- AXDX Biotechnology: Laboratory Analytical Instruments
- Sector
- HOLO Technology
- AXDX Industrials
- Exchange
- HOLO Nasdaq
- AXDX Nasdaq
- Market Cap
- HOLO 50.1M
- AXDX 41.8M
- IPO Year
- HOLO N/A
- AXDX 1996
- Fundamental
- Price
- HOLO $1.33
- AXDX $1.20
- Analyst Decision
- HOLO
- AXDX Hold
- Analyst Count
- HOLO 0
- AXDX 1
- Target Price
- HOLO N/A
- AXDX $1.00
- AVG Volume (30 Days)
- HOLO 3.9M
- AXDX 63.7K
- Earning Date
- HOLO 02-08-2025
- AXDX 11-07-2024
- Dividend Yield
- HOLO N/A
- AXDX N/A
- EPS Growth
- HOLO N/A
- AXDX N/A
- EPS
- HOLO N/A
- AXDX N/A
- Revenue
- HOLO $32,242,196.00
- AXDX $11,909,000.00
- Revenue This Year
- HOLO N/A
- AXDX $1.50
- Revenue Next Year
- HOLO N/A
- AXDX $4.17
- P/E Ratio
- HOLO N/A
- AXDX N/A
- Revenue Growth
- HOLO 326.95
- AXDX N/A
- 52 Week Low
- HOLO $1.26
- AXDX $0.73
- 52 Week High
- HOLO $1,968.00
- AXDX $4.68
- Technical
- Relative Strength Index (RSI)
- HOLO 26.60
- AXDX 23.69
- Support Level
- HOLO $1.28
- AXDX $1.32
- Resistance Level
- HOLO $1.60
- AXDX $1.42
- Average True Range (ATR)
- HOLO 0.16
- AXDX 0.12
- MACD
- HOLO 0.03
- AXDX -0.04
- Stochastic Oscillator
- HOLO 2.75
- AXDX 2.63
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About AXDX Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.